Use of blocking-reagents for reducing unspecific t cell-activation
OwnerGundram JUNG, Helmut SALIH +2inventors
InventorsGundram JUNG, Helmut SALIH, Fabian VOGT, Joseph KAUER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a blocking-reagent for use in reducing unspecific T cell activation in T cell engaging therapies. The present invention further relates to pharmaceutical kit of parts and an in vitro method for evaluating unspecific T cell activation.
Claims15
A method for reducing unspecific T cell activation in a therapy, the method comprising co-administering to a subject a blocking-reagent together with the therapy, the therapy comprising a bispecific antibody molecule and/or a chimeric antigen receptor (CAR) modified T cell,
- wherein the bispecific antibody molecule comprises two binding sites
- i) wherein the first binding site binds to an antigen associated with a target cell and
- ii) wherein the second binding site binds to a T cell receptor (TCR)/CD3 complex, on an effector cell and/or
- wherein the CAR comprises
- iii) an antibody molecule comprising a binding site that binds to an antigen associated with a target cell, and
- iv) a TCR/CD3 signaling domain.
A pharmaceutical kit of parts, comprising in two separate parts:
- a) a blocking-reagent, and
- b) a bispecific antibody molecule and/or a chimeric antigen receptor (CAR) modified T cell,
- wherein the bispecific antibody molecule binds to
- i) a first antigen, and
- ii) a T cell receptor (TCR)/CD3 complex and/or
- wherein the CAR comprises
- i) an antibody molecule, and
- ii) a TCR/CD3 signaling domain.
(canceled)
Dependencies are inferred from the claim text.